MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Garralda, Elena; Beaulieu, Marie-Ève; Moreno, Víctor; Casacuberta‐Serra, Sílvia; Martínez-Martín, Sandra; Foradada, Laia; Alonso, Guzmán; Massó-Vallés, Daniel; López‐Estévez, Sergio; Jauset, Toni; Corral de la Fuente, E.; Doger, Bernard; Hernández, Tatiana; Pérez-López, Raquel; Arqués, Oriol; Castillo Cano, Virginia; Ruíz Morales, Josefa; R. Whitfield, Jonathan; Niewel, Manuela; Soucek, Laura; Calvo, Emiliano

doi:10.1038/s41591-024-02805-1

Public

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Published in Nature Medicine • Feb 6, 2024

Authors:

Elena Garralda

Marie-Ève Beaulieu

Víctor Moreno

Abstract

Abstract Among the ‘most wanted’ targets in cancer therapy is the oncogene MYC, which coordinates key transcriptional programs in tumor development and maintenance. It has, however, long been considered undruggable. OMO-103 is a MYC inhibitor consisting of a 91-amino acid miniprotein. Here we presen...

Subject

Tolerability

Pharmacokinetics

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!